secwatch.observer — SEC 8-K summary
======================================

Issuer:     Totaligent, Inc. (TGNT)
CIK:        0000846377
Form:       8-K
Filed at:   2026-02-25T23:59:59+00:00
Accession:  0001477932-26-001016
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Totaligent signs binding LOI for JV with GloMed and call option to acquire GloMed for $3M cash + 15% equity
--------------------------------------------------------------------------------

- GloMed has ~$10M annual revenue and ~$1M free cash flow; distributes biologics/devices in APAC via 20+ KOLs.
- JV will combine Aetherium Medical platform with GloMed's infrastructure; no upfront cash; incremental revenue shared.
- Call option to buy 100% of GloMed within 1 year for $3M cash plus 15% of Totaligent's fully diluted common stock.
- Target JV closing March 22, 2026; subject to due diligence, definitive agreements, and PCAOB audit for option exercise.
- Exclusivity through April 22, 2026; board seats: DeFeudis, Heath, Klarich; Totaligent appoints 3 seats for strategic control.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/846377/000147793226001016/0001477932-26-001016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/846377/000147793226001016/totaligent_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-26-001016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer